Castle Biosciences Expects 2025 Total Revenue to Exceed $340 Million
2025 total revenue expected to exceed $340 million, above the previously guided range of $327-335 million. "We are extremely pleased with our excellent fourth quarter and full year preliminary results, which reflect both the strength of our innovative test portfolio and the dedication of the entire Castle team," said Derek Maetzold, president and chief executive officer of Castle Biosciences.
